vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and GREAT SOUTHERN BANCORP, INC. (GSBC). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $56.4M, roughly 1.4× GREAT SOUTHERN BANCORP, INC.). GREAT SOUTHERN BANCORP, INC. runs the higher net margin — 28.9% vs -9.6%, a 38.5% gap on every dollar of revenue. On growth, GREAT SOUTHERN BANCORP, INC. posted the faster year-over-year revenue change (-0.2% vs -16.8%). Over the past eight quarters, GREAT SOUTHERN BANCORP, INC.'s revenue compounded faster (4.5% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

BIOX vs GSBC — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.4× larger
BIOX
$77.6M
$56.4M
GSBC
Growing faster (revenue YoY)
GSBC
GSBC
+16.6% gap
GSBC
-0.2%
-16.8%
BIOX
Higher net margin
GSBC
GSBC
38.5% more per $
GSBC
28.9%
-9.6%
BIOX
Faster 2-yr revenue CAGR
GSBC
GSBC
Annualised
GSBC
4.5%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
GSBC
GSBC
Revenue
$77.6M
$56.4M
Net Profit
$-7.4M
$16.3M
Gross Margin
46.8%
Operating Margin
9.3%
34.5%
Net Margin
-9.6%
28.9%
Revenue YoY
-16.8%
-0.2%
Net Profit YoY
-20.2%
9.1%
EPS (diluted)
$-0.12
$1.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
GSBC
GSBC
Q4 25
$56.4M
Q3 25
$77.6M
$57.8M
Q2 25
$59.2M
Q1 25
$60.6M
$55.9M
Q4 24
$98.8M
$56.5M
Q3 24
$93.3M
$55.0M
Q2 24
$56.7M
Q1 24
$84.0M
$51.6M
Net Profit
BIOX
BIOX
GSBC
GSBC
Q4 25
$16.3M
Q3 25
$-7.4M
$17.8M
Q2 25
$19.8M
Q1 25
$-1.6M
$17.2M
Q4 24
$605.2K
$14.9M
Q3 24
$-6.2M
$16.5M
Q2 24
$17.0M
Q1 24
$9.8M
$13.4M
Gross Margin
BIOX
BIOX
GSBC
GSBC
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
GSBC
GSBC
Q4 25
34.5%
Q3 25
9.3%
38.2%
Q2 25
41.0%
Q1 25
1.5%
38.4%
Q4 24
14.5%
31.8%
Q3 24
2.5%
36.6%
Q2 24
36.8%
Q1 24
15.7%
32.1%
Net Margin
BIOX
BIOX
GSBC
GSBC
Q4 25
28.9%
Q3 25
-9.6%
30.7%
Q2 25
33.4%
Q1 25
-2.6%
30.7%
Q4 24
0.6%
26.4%
Q3 24
-6.6%
30.0%
Q2 24
30.0%
Q1 24
11.6%
26.0%
EPS (diluted)
BIOX
BIOX
GSBC
GSBC
Q4 25
$1.44
Q3 25
$-0.12
$1.56
Q2 25
$1.72
Q1 25
$-0.02
$1.47
Q4 24
$0.00
$1.27
Q3 24
$-0.10
$1.41
Q2 24
$1.45
Q1 24
$0.14
$1.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
GSBC
GSBC
Cash + ST InvestmentsLiquidity on hand
$15.5M
$189.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$636.1M
Total Assets
$734.9M
$5.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
GSBC
GSBC
Q4 25
$189.6M
Q3 25
$15.5M
$196.2M
Q2 25
$245.9M
Q1 25
$38.5M
$217.2M
Q4 24
$29.2M
$195.8M
Q3 24
$32.3M
$208.4M
Q2 24
$186.5M
Q1 24
$16.4M
$171.4M
Stockholders' Equity
BIOX
BIOX
GSBC
GSBC
Q4 25
$636.1M
Q3 25
$288.3M
$632.9M
Q2 25
$622.4M
Q1 25
$345.0M
$613.3M
Q4 24
$346.3M
$599.6M
Q3 24
$346.0M
$612.1M
Q2 24
$568.8M
Q1 24
$348.5M
$565.2M
Total Assets
BIOX
BIOX
GSBC
GSBC
Q4 25
$5.6B
Q3 25
$734.9M
$5.7B
Q2 25
$5.9B
Q1 25
$798.2M
$6.0B
Q4 24
$835.2M
$6.0B
Q3 24
$827.3M
$6.0B
Q2 24
$6.0B
Q1 24
$836.1M
$5.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
GSBC
GSBC
Operating Cash FlowLast quarter
$14.4M
$81.5M
Free Cash FlowOCF − Capex
$70.1M
FCF MarginFCF / Revenue
124.3%
Capex IntensityCapex / Revenue
20.3%
Cash ConversionOCF / Net Profit
5.01×
TTM Free Cash FlowTrailing 4 quarters
$121.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
GSBC
GSBC
Q4 25
$81.5M
Q3 25
$14.4M
$5.6M
Q2 25
$39.3M
Q1 25
$23.3M
$15.0M
Q4 24
$-5.4M
$44.1M
Q3 24
$5.2M
$17.7M
Q2 24
$43.5M
Q1 24
$-17.4M
$-26.9M
Free Cash Flow
BIOX
BIOX
GSBC
GSBC
Q4 25
$70.1M
Q3 25
$3.9M
Q2 25
$34.9M
Q1 25
$13.1M
Q4 24
$39.1M
Q3 24
$16.5M
Q2 24
$42.0M
Q1 24
$-27.7M
FCF Margin
BIOX
BIOX
GSBC
GSBC
Q4 25
124.3%
Q3 25
6.7%
Q2 25
59.0%
Q1 25
23.4%
Q4 24
69.3%
Q3 24
30.1%
Q2 24
74.1%
Q1 24
-53.7%
Capex Intensity
BIOX
BIOX
GSBC
GSBC
Q4 25
20.3%
Q3 25
3.0%
Q2 25
7.4%
Q1 25
3.5%
Q4 24
8.7%
Q3 24
2.1%
Q2 24
2.7%
Q1 24
1.6%
Cash Conversion
BIOX
BIOX
GSBC
GSBC
Q4 25
5.01×
Q3 25
0.31×
Q2 25
1.99×
Q1 25
0.87×
Q4 24
-8.85×
2.95×
Q3 24
1.07×
Q2 24
2.56×
Q1 24
-1.78×
-2.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons